An estimated 50,000 mCRPC patients each year could benefit from knowing their AR-V7 status
It’s estimated that about 50,000 metastatic castration-resistant prostate cancer (mCRPC) patients each year could benefit from knowing their AR-V7 status prior to selecting treatment. Patients who are resistant to androgen receptor (AR)-targeted therapies, such as abiraterone or enzalutamide, often respond to taxane chemotherapy.1,2,3 The Oncotype DX AR-V7 Nucleus Detect test can help you confidently choose the therapy that will help offer your patients the opportunity for longer overall survival.
The AR-V7 Nucleus Detect assay is an option if:
- Your patient has mCRPC.
- The patient has received and failed AR-targeted therapy.
- Another AR-targeted therapy is being considered.
When to order the AR-V7 Nucleus Detect test
Ordering the AR-V7 Nucleus Detect test is appropriate for patients with mCRPC whenever you’re considering AR-targeted therapy for a patient.
Why order the test before ordering AR-targeted therapies
Although AR-targeted therapies are a breakthrough in mCRPC treatment, it’s important to remember that some patients never respond to AR-targeted therapies and many patients who initially respond to AR-targeted therapies develop acquired resistance to them over time.4
The percentage of patients who are nuclear AR-V7+ (an absolute indicator that a patient will not respond to AR-targeted therapies) increases with each exposure to AR-targeted therapies5:
- Roughly 1 in 5 patients (18%) are nuclear AR-V7+ after receiving abiraterone or enzalutamide.
- Roughly 1 in 3 patients (31%) are nuclear AR-V7+ after receiving two rounds of AR-targeted therapy.
The percentage of mCRPC patients with the AR splice variant (AR-V7+) increased with continued exposure to AR-targeted therapies5
Cross-sectional cohort study. Blood samples were collected from 161 patients with mCRPC and tested for the presence of AR-V7.